Bioceres Crop Solutions (BIOX) Cash & Equivalents (2016 - 2026)

Bioceres Crop Solutions has reported Cash & Equivalents for 11 years, with the latest figure at $14.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 67.62% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (down 67.62% YoY) and the FY2025 annual result came in at $44.5 million, down 7.6% from the prior year.
• Cash & Equivalents slipped to $14.4 million in Q1 2026 per BIOX's latest filing, from $32.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $68.6 million in Q4 2022 and troughed at $14.4 million in Q1 2026.
• A 5-year average of $42.9 million and a median of $44.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents soared 88.5% in 2022, then tumbled 67.62% in 2026.
• Over 5 years, Cash & Equivalents stood at $68.6 million in 2022, then dropped by 29.79% to $48.1 million in 2023, then slipped by 7.6% to $44.5 million in 2024, then fell by 26.48% to $32.7 million in 2025, then sank by 55.96% to $14.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $14.4 million, $32.7 million, and $32.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.